Scotland is world’s first country to greenlight Tagrisso for NSCLCScotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small Share XScotland is world’s first country to greenlight Tagrisso for NSCLChttps://pharmaphorum.com/news/scotland-is-worlds-first-country-to-greenlight-tagrisso-for-nsclc/
Opdivo and chemotherapy combo increases survival in lung cancer patientsLung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable Share XOpdivo and chemotherapy combo increases survival in lung cancer patientshttps://pharmaphorum.com/news/opdivo-chemotherapy-combo-increases-survival-lung-cancer-patients/
Strike two for Novartis’ lung cancer antibody canakinumabExpectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 Share XStrike two for Novartis’ lung cancer antibody canakinumabhttps://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/
Good news for Lilly as sintilimab hits the spot in lung cancer againEli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s Share XGood news for Lilly as sintilimab hits the spot in lung cancer againhttps://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/
Roche scores adjuvant lung cancer approval for TecentriqRoche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), Share XRoche scores adjuvant lung cancer approval for Tecentriqhttps://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/
NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
AI ‘could help diagnose lung cancer a year earlier’An artificial intelligence algorithm was able to detect signs of lung cancer on CT scans a year earlier Share XAI ‘could help diagnose lung cancer a year earlier’https://pharmaphorum.com/news/ai-could-help-diagnose-lung-cancer-a-year-earlier/
J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ techThree years ago, Johnson & Johnson set up a wide-ranging initiative with Boston University to try to improve Share XJ&J lung cancer initiative will use Optellum’s ‘digital biomarker’ techhttps://pharmaphorum.com/news/jj-teams-up-with-optellum-on-digital-biomarker-tech-lung-cancer/
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
